Impact of anti-CD20 monoclonal antibodies on serologic response to

Antibodies, Free Full-Text

Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy

Rituximab for the treatment of multiple sclerosis: a review

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies

Vaccines, Free Full-Text

Frontiers B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice

Mechanisms of killing by anti-CD20 monoclonal antibodies - ScienceDirect

Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies

Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis - eBioMedicine

Establishment of C20Mab‑11, a novel anti‑CD20 monoclonal antibody, for the detection of B cells

Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico: Cell

Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies